CEGEDIM SA (CGM.PA) Stock Fundamental Analysis
EPA:CGM - Euronext Paris - Matif - FR0000053506 - Common Stock - Currency: EUR
CGM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 13 industry peers in the Health Care Technology industry. Both the profitability and financial health of CGM have multiple concerns. CGM has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CGM has reported negative net income.
CGM had a positive operating cash flow in the past year.
In multiple years CGM reported negative net income over the last 5 years.
CGM had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
CGM has a Return On Assets (-1.49%) which is in line with its industry peers.
The Return On Equity of CGM (-5.56%) is comparable to the rest of the industry.
Looking at the Return On Invested Capital, with a value of 4.46%, CGM is in line with its industry, outperforming 53.85% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for CGM is significantly below the industry average of 9.30%.
The 3 year average ROIC (2.87%) for CGM is below the current ROIC(4.46%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.49% | ||
| ROE | -5.56% | ||
| ROIC | 4.46% |
ROA(3y)-0.25%
ROA(5y)0.74%
ROE(3y)-1.16%
ROE(5y)2.61%
ROIC(3y)2.87%
ROIC(5y)3.89%
1.3 Margins
CGM's Operating Margin of 5.75% is in line compared to the rest of the industry. CGM outperforms 46.15% of its industry peers.
CGM's Operating Margin has declined in the last couple of years.
CGM has a Gross Margin of 20.07%. This is in the lower half of the industry: CGM underperforms 76.92% of its industry peers.
In the last couple of years the Gross Margin of CGM has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.75% | ||
| PM (TTM) | N/A | ||
| GM | 20.07% |
OM growth 3Y-6.64%
OM growth 5Y-3.53%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.96%
GM growth 5Y-1.7%
2. Health
2.1 Basic Checks
CGM has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
CGM has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CGM has been reduced compared to 5 years ago.
Compared to 1 year ago, CGM has a worse debt to assets ratio.
2.2 Solvency
CGM has an Altman-Z score of 1.29. This is a bad value and indicates that CGM is not financially healthy and even has some risk of bankruptcy.
CGM's Altman-Z score of 1.29 is in line compared to the rest of the industry. CGM outperforms 53.85% of its industry peers.
The Debt to FCF ratio of CGM is 27.31, which is on the high side as it means it would take CGM, 27.31 years of fcf income to pay off all of its debts.
CGM's Debt to FCF ratio of 27.31 is in line compared to the rest of the industry. CGM outperforms 53.85% of its industry peers.
CGM has a Debt/Equity ratio of 1.14. This is a high value indicating a heavy dependency on external financing.
CGM has a Debt to Equity ratio of 1.14. This is in the lower half of the industry: CGM underperforms 61.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.14 | ||
| Debt/FCF | 27.31 | ||
| Altman-Z | 1.29 |
ROIC/WACC1.05
WACC4.25%
2.3 Liquidity
A Current Ratio of 0.99 indicates that CGM may have some problems paying its short term obligations.
CGM has a worse Current ratio (0.99) than 61.54% of its industry peers.
A Quick Ratio of 0.97 indicates that CGM may have some problems paying its short term obligations.
CGM has a Quick ratio of 0.97. This is in the lower half of the industry: CGM underperforms 61.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.97 |
3. Growth
3.1 Past
The earnings per share for CGM have decreased strongly by -97.97% in the last year.
CGM shows a small growth in Revenue. In the last year, the Revenue has grown by 6.25%.
Measured over the past years, CGM shows a small growth in Revenue. The Revenue has been growing by 5.38% on average per year.
EPS 1Y (TTM)-97.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1194.13%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y7.65%
Revenue growth 5Y5.38%
Sales Q2Q%6.51%
3.2 Future
The Earnings Per Share is expected to grow by 24.45% on average over the next years. This is a very strong growth
Based on estimates for the next years, CGM will show a small growth in Revenue. The Revenue will grow by 3.51% on average per year.
EPS Next Y30.09%
EPS Next 2Y24.45%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.92%
Revenue Next 2Y3.51%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CGM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 8.05, the valuation of CGM can be described as reasonable.
Based on the Price/Forward Earnings ratio, CGM is valued cheaper than 100.00% of the companies in the same industry.
CGM is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.20, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 8.05 |
4.2 Price Multiples
92.31% of the companies in the same industry are more expensive than CGM, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, CGM is valued cheaply inside the industry as 92.31% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.12 | ||
| EV/EBITDA | 3.39 |
4.3 Compensation for Growth
CGM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CGM's earnings are expected to grow with 24.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.45%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CGM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:CGM (4/30/2025, 7:00:00 PM)
11.95
-0.15 (-1.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners17.48%
Inst Owner ChangeN/A
Ins Owners54.22%
Ins Owner ChangeN/A
Market Cap168.50M
Analysts48.89
Price Target15.56 (30.21%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.16%
PT rev (3m)-4.84%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-6.67%
EPS NY rev (3m)-3.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.47%
Revenue NY rev (3m)-2.61%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 8.05 | ||
| P/S | 0.26 | ||
| P/FCF | 14.12 | ||
| P/OCF | 1.65 | ||
| P/B | 0.64 | ||
| P/tB | N/A | ||
| EV/EBITDA | 3.39 |
EPS(TTM)-1.07
EYN/A
EPS(NY)1.48
Fwd EY12.42%
FCF(TTM)0.85
FCFY7.08%
OCF(TTM)7.22
OCFY60.45%
SpS46.42
BVpS18.75
TBVpS-11.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.49% | ||
| ROE | -5.56% | ||
| ROCE | 6.06% | ||
| ROIC | 4.46% | ||
| ROICexc | 4.84% | ||
| ROICexgc | 19.22% | ||
| OM | 5.75% | ||
| PM (TTM) | N/A | ||
| GM | 20.07% | ||
| FCFM | 1.82% |
ROA(3y)-0.25%
ROA(5y)0.74%
ROE(3y)-1.16%
ROE(5y)2.61%
ROIC(3y)2.87%
ROIC(5y)3.89%
ROICexc(3y)3.13%
ROICexc(5y)4.15%
ROICexgc(3y)11.62%
ROICexgc(5y)15.26%
ROCE(3y)3.91%
ROCE(5y)5.29%
ROICexcg growth 3Y0.21%
ROICexcg growth 5Y-3.19%
ROICexc growth 3Y-3.24%
ROICexc growth 5Y-2.52%
OM growth 3Y-6.64%
OM growth 5Y-3.53%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.96%
GM growth 5Y-1.7%
F-Score3
Asset Turnover0.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.14 | ||
| Debt/FCF | 27.31 | ||
| Debt/EBITDA | 2.3 | ||
| Cap/Depr | 96.22% | ||
| Cap/Sales | 13.74% | ||
| Interest Coverage | 4.24 | ||
| Cash Conversion | 77.7% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.97 | ||
| Altman-Z | 1.29 |
F-Score3
WACC4.25%
ROIC/WACC1.05
Cap/Depr(3y)92.57%
Cap/Depr(5y)94.88%
Cap/Sales(3y)13.24%
Cap/Sales(5y)13.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-97.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1194.13%
EPS Next Y30.09%
EPS Next 2Y24.45%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)6.25%
Revenue growth 3Y7.65%
Revenue growth 5Y5.38%
Sales Q2Q%6.51%
Revenue Next Year2.92%
Revenue Next 2Y3.51%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y79.81%
EBIT growth 3Y0.5%
EBIT growth 5Y1.66%
EBIT Next Year284.62%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-46.81%
FCF growth 3Y-27.43%
FCF growth 5YN/A
OCF growth 1Y4.01%
OCF growth 3Y2%
OCF growth 5Y28.33%